Profile of multi drug resistant (MDR) and rifampicin resistant TB patients treated under category IV of RNTCP

Authors

  • Pravin Uike Department of Pharmacology, SVN Govt. Medical College, Yavatmal, Maharashtra, India
  • Prabhakar Hiwarkar Department of Community Medicine, SVN Govt. Medical College, Yavatmal, Maharashtra, India
  • Vilas Malkar Department of Community Medicine, SVN Govt. Medical College, Yavatmal, Maharashtra, India
  • Ketan Aswalle Department of Community Medicine, SVN Govt. Medical College, Yavatmal, Maharashtra, India

DOI:

https://doi.org/10.18203/2319-2003.ijbcp20170992

Keywords:

MDR-TB, Rifampicin resistant, RNTCP Category IV, STR

Abstract

Background: The emergence of resistance to drugs used to treat tuberculosis (TB) and particularly multidrug resistance TB (MDR-TB) has become a significant health problem and obstacle to effective TB control in India. Present study was conducted to study clinical and sociodemograohic profile of MDR and rifampicin resistant TB patients registered for treatment under RNTCP in Yavatmal district of Maharashtra state.

Methods: All drug resistant (MDR and rifampicin resistant) TB patients residents of Yavatmal district, treated at DOTS plus site with Standardized Treatment Regimen (STR) from 1st quarter 2009 to 3rd quarter 2013 were included. Data was obtained from electronic treatment register maintained at DOTS Plus site.

Results: There were total 60 confirmed MDR and rifampicin resistant TB patients from Yavatmal district. Male patients (65.00%) were comparatively more than females (35.00%). Almost half (46.67%) of the patients belonged to the productive age group i.e. 30-45 years followed by another one third (35.00%) in the age group of 15-30 years. 93.33% patients were previously treated under RNTCP (under CAT II), out of them 48.51% were failure, 37.50% relapse and 14.29% defaulter.

Conclusions: Among MDR and rifampicin resistant TB patients, maximum patients were males, belonged to the social and productive age group, HIV negative and previously treated due to treatment failure.

References

Central TB Division. Guidelines on Programmatic Management of Drug Resistant TB (PMDT) in India. Central TB Division. 2012;124. Available from: http://tbcindia.gov.in/WriteReadData/l892s/8320929355Guidelines for PMDT in India - May 2012.pdf%5Cnhttp://www.tbcindia.gov.in/showfile.php?lid=3155

Mahadev B, Kumar P, Agarwal SP, Chauhan LS, Srikantaramu N. Surveillance of drug resistance to anti-tuberculosis drugs in districts of Hoogli in West Bengal and Mayurbhanj in Orissa. Indian J Tuberc. 2005;52:5-10.

Paramasivan CN, Venkataraman R, Chandrasekaran V, Bhat S, Narayanan RR. Surveillance of drug resistance in tuberculosis in two districts of South India. Int J Tuberc Lung Dis. 2002;6(6):479-84.

Jain K, Desai M, Solanki R, Dikshit RK. Treatment outcome of standardized regimen in patients with multidrug resistant tuberculosis. J Pharmacol Pharmacother. 2014;5:145-9.

World Health Organization, Joint Monitoring Mission for Revised National Tuberculosis Control Programme. SEARO. World Health Organization, South-East Asia Regional Office; 2016.

Sharma SK, Kumar S, Saha PK, George N, Arora SK, Gupta D, et al. Prevalence of multidrug-resistant tuberculosis among Category II pulmonary tuberculosis patients. Indian J Med Res. 2011;133(3):312-5.

Kapadia VK, Sanjay T. Analysis of 63 patients of MDR TB on DOTS plus regimen : An LG hospital, TB Unit, Ahmedabad experience.

Teixeira L, Perkins MD, Johnson JL, Keller R, Palaci M, Do Valle Dettoni V, et al. Infection and disease among household contacts of patients with multidrug-resistant tuberculosis. Int J Tuberc Lung Dis. 2001;5(4):321-8.

Bayona J, Chavez-Pachas AM, Palacios E, Llaro K, Sapag R, Becerra MC. Contact investigations as a means of detection and timely treatment of persons with infectious multidrug-resistant tuberculosis. Vol. 7, International Journal of Tuberculosis and Lung Disease; 2003:S501-9.

Bhatt G, Vyas S, Trivedil K. An epidemiological study of multi drug resistant tuberculosis cases registered under Revised National Tuberculosis Control Programme of Ahmedabad City. Indian J Tuberc. 2012;59(1):18-27.

Joseph P, Desai VBR, Mohan NS, Fredrick JS, Ramachandran R, Raman B, et al. Outcome of standardized treatment for patients with MDR-TB from Tamil Nadu, India. Indian J Med Res. 2011;133(5):529-34.

Vella V, Racalbuto V, Guerra R, Marra C, Moll A, Mhlanga Z, et al. Household contact investigation of multidrug-resistant and extensively drug-resistant tuberculosis in a high HIV prevalence setting. Int J Tuberc Lung Dis. 2011;15(9):1170-5.

Caetano Mota P, Carvalho A, Valente I, Braga R, Duarte R. Predictors of delayed sputum smears and culture conversion among a Portuguese population with pulmonary tuberculosis. Rev Port Pneumol 2012;18(2):72-9.

Bhatt G, Vyas S, Trivedil K. An epidemiological study of multi drug resistant tuberculosis cases registered under Revised National Tuberculosis Control Programme of Ahmedabad City. Indian J Tuberc. 2012;59(1):18-27.

Downloads

Published

2017-03-25

How to Cite

Uike, P., Hiwarkar, P., Malkar, V., & Aswalle, K. (2017). Profile of multi drug resistant (MDR) and rifampicin resistant TB patients treated under category IV of RNTCP. International Journal of Basic & Clinical Pharmacology, 6(4), 784–787. https://doi.org/10.18203/2319-2003.ijbcp20170992

Issue

Section

Original Research Articles